Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental antibody drug shows promise for Hard-to-Treat lymphoma

NCT ID NCT05927558

Disease control Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Jul 29, 2026 · Updated 5 times

Summary

This study looks at how well the drug glofitamab works in adults with B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. Researchers are tracking how many patients achieve a complete response after receiving glofitamab through a compassionate use program. The goal is to see if this therapy can help people who have few other options.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
glofitamab
What this could lead to
If successful, this could show that glofitamab is an effective treatment option for patients with hard-to-treat B-cell lymphoma who have few alternatives.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. The drug is given through a compassionate use program, meaning patients are very sick and outcomes may not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

59 people

The number who actually took part.

Started

Dec 2023

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with refractory/relapsed B-cell non-Hodgkin lymphoma treated in Italy according to the Compassionate Use Program between March 2022 and September 2023

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients who received glofitamab according to Compassionate Use Program AG42296 2. Age \> 18 years 3. Patients who received at least one dose of glofitamab between March 2022 and September 2023 in the context of the compassionate use program and who completed at least 1 year of observation after last glofitamab administration unless the patient died or was lost to follow up 4. Patients who provided their consent according to local regulation to collect their data for study purposes, dead patients or patients lost to follow up for which any attempt has been made to collect their consent, according to local regulation on data privacy Exclusion Criteria: * None

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-cell non Hodgkin lymphoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm B-cell non-Hodgkin lymphoma lymphoma Recurrence refractory malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-cell non Hodgkin lymphoma Refractory lymphoma Relapse

Contacts and locations

Locations

  • Ematologia Istituto Nazionale Tumori

    Milan, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.